spacer
home > ebr > summer 2019 > the dna of a new industry
PUBLICATIONS
European Biopharmaceutical Review

The DNA of a New Industry

Advancements in science, combined with new and affordable technology, have created a fertile ground for biotechnology entrepreneurs. 23andMe launched the first direct-to-consumer (DTC) genomics test back in 2007. The initial price tag was US $1,000, but this was to go down very rapidly. In the next few years, 23andMe experimented with different business and pricing models, including subscription.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Efi Binder is a serial entrepreneur in the field of biotechnology and the co-founder and CEO of Israel’s first DTC genomics company, Futura Genetics. Before becoming the CEO of Futura Genetics, he co-founded Mosteq, a company developing novel biological control methods for deadly mosquitoes. Efi was also on the founding team of primal data, a facilitator of data transfer for medical research use. Before venturing on his entrepreneurial career, he spent three years working as a management consultant for top tier firms, helping big corporates define their long-term strategy. Efi is a Hebrew University, Israel, alumni with a BA in economics and an MBA.
spacer
Efi Binder
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta and Cytiva collaborating on COVID-19 rapid test

Cambridge and Wetherby, UK, 08 April 2020: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Cytiva, formerly known as GE Healthcare Life Sciences. The companies will develop and manufacture an Affimer-based point-of-care rapid test intended for screening of large populations to diagnose the COVID-19 coronavirus infection.
More info >>

White Papers

Clinical Trial-Specific Travel Programs as a Patient Retention Tool

For many patients, participating in a clinical trial is a major endeavor. Depending on the protocol requirements, study visits can be exhausting. There are a number of reasons why a patient may choose to participate in a trial only to drop out. Conversely, there are several approaches to proactively try to prevent this from happening. There are various methods professionals implement for patient retention. This white paper explores patient travel services as one patient retention strategy.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement